V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310004984 | 310002260 | null | null | Curative (C) | 2016-06-07 | 2016-07-03 | Bevacizumab 7.5mg/kg | 02 | Y | 310024932 | CYCLOPHOSPHAMIDE |
| 310004985 | 310002261 | 1.88 | 76.4 | Palliative (P) | 2018-04-11 | 2018-04-28 | DA-EPOCH-R | Y | N | 310024945 | DABRAFENIB |
| 310004986 | 310002262 | 1.73 | 78.3 | Palliative (P) | 2017-12-01 | 2017-12-03 | CMV | N | N | 310024957 | LEAM |
| 310004987 | 310002263 | 1.77 | 78.2 | Curative (C) | 2015-09-19 | 2015-09-26 | Cisplatin + Pemetrexed | Y | N | 310024959 | BRENTUXIMAB |
| 310004988 | 310002263 | 1.6 | 88 | Curative (C) | null | 2016-08-20 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | N | N | 310024959 | DABRAFENIB |
| 310004989 | 310002263 | 1.48 | 80.4 | Curative (C) | 2017-09-21 | 2017-09-25 | Azacitidine | 2 | N | 310024959 | IVA |
| 310004990 | 310002264 | 1.81 | 96.4 | Palliative (P) | 2016-01-14 | 2016-06-04 | DABRAFENIB | 02 | N | 310024976 | CAPECITABINE + CISPLATIN + RT |
| 310004991 | 310002265 | 1.72 | null | Palliative (P) | 2014-12-31 | 2015-01-03 | BEP 5 Day | 02 | N | 310024980 | IVE |
| 310004992 | 310002265 | 1.7 | 94 | Adjuvant (A) | 2011-12-25 | 2015-01-04 | Pazopanib | 2 | N | 310024980 | DOXORUBICIN + OLARATUMAB |
| 310004993 | 310002266 | 1.7 | null | Curative (C) | 2016-01-11 | 2016-01-29 | Triple Intrathecal | Y | null | 310024987 | MITOMYCIN |
| 310004994 | 310002267 | 1.69 | 90 | Palliative (P) | 2013-02-12 | 2013-02-15 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 310024988 | BEVACIZUMAB + CARBO |
| 310004995 | 310002268 | 1.77 | null | null | 2016-11-18 | 2016-12-04 | GEMCITABINE + NAB PACLITAXEL | 02 | N | 310024989 | CARBO + FLUOROURACIL |
| 310004997 | 310002269 | 1.8 | 89.7 | Adjuvant (A) | 2017-12-11 | 2017-12-18 | R GDP | N | N | 310025003 | CYTARABINE + METHOTREXATE + RITUXIMAB + THIOTEPA |
| 310004998 | 310002269 | 1.67 | 96 | Curative (C) | 2016-04-29 | 2015-01-01 | CMV | 2 | N | 310025003 | BEVACIZUMAB |
| 310004999 | 310002269 | 1.72 | 95.4 | Palliative (P) | 2015-04-29 | 2015-04-29 | Carboplatin+Fluorouracil 4 or 5 day | 2 | N | 310025003 | CHLORAMBUCIL |
| 310005000 | 310002270 | 1.56 | 0 | Disease modification (D) | 2015-07-24 | 2015-08-15 | CYCLOPHOSPHAMIDE | Y | Y | 310025011 | IVE |
| 310005001 | 310002271 | 1.48 | 58.1 | Curative (C) | 2016-08-28 | 2016-08-29 | Bevacizumab + CARBOPLATIN + GEMCITABINE | 99 | N | 310025017 | DABRAFENIB + TRAMETINIB |
| 310005002 | 310002272 | null | 55 | Curative (C) | 2013-04-22 | 2013-04-26 | ICON8B TRIAL | N | N | 310025022 | PAZOPANIB |
| 310005003 | 310002273 | 1.71 | 83.7 | Palliative (P) | 2017-04-27 | 2017-05-14 | Cisplatin + Fluorouracil + RT 5day | N | null | 310025024 | RCEOP |
| 310005004 | 310006945 | 1.68 | 61.1 | null | 2013-09-02 | 2014-04-08 | ICE-R | 02 | N | 310025037 | CARBO + FLUOROURACIL |
| 310005005 | 310009242 | 1.55 | 98.41 | Curative (C) | 2016-04-10 | 2016-04-23 | Bortezomib +/- Dexamethasone | 2 | N | 310025038 | IVA |
| 310005006 | 310002274 | 1.7 | 87.7 | Adjuvant (A) | 2015-05-12 | 2015-05-12 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | null | null | 310025048 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 310005007 | 310002275 | 0 | 93.8 | Curative (C) | 2015-03-04 | 2015-03-04 | Cyclophosphamide Fludarabine (Oral) | null | N | 310025049 | PERM TRIAL |
| 310005008 | 310002276 | 1.6 | 83 | Curative (C) | 2015-05-24 | 2015-06-04 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 310025069 | IRINOTECAN |
| 310005009 | 310002277 | 1.85 | 72.1 | Disease modification (D) | 2015-06-05 | 2015-06-22 | TAC | N | N | 310025070 | DABRAFENIB |
| 310005010 | 310002277 | 1.53 | null | Palliative (P) | 2014-10-18 | 2014-10-25 | CVP R | null | N | 310025070 | CYCLOPHOSPHAMIDE |
| 310005011 | 310009243 | null | 72.6 | Curative (C) | 2016-08-16 | 2016-09-01 | DABRAFENIB | 02 | null | 310025086 | CISPLATIN + TOPOTECAN |
| 310005012 | 310010435 | null | null | Palliative (P) | 2018-03-26 | 2018-03-26 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 2 | null | 310025087 | NIVOLUMAB |
| 310005013 | 310011094 | 1.63 | 70 | null | null | 2013-10-14 | CETUXIMAB | N | null | 310025096 | ECARBOX |
| 310005014 | 310011466 | 1.79 | 0 | Palliative (P) | 2015-03-27 | 2015-04-23 | R-GEM-P | 02 | N | 310025103 | CETUXIMAB + CISPLATIN + FLUOROURACIL |
| 310005015 | 310002278 | 1.81 | 90.66 | Curative (C) | 2013-09-27 | 2013-09-27 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | Y | 310025106 | UKALL 2011 |
| 310005016 | 310006947 | 1.71 | 70.35 | Curative (C) | 2014-07-05 | 2014-07-14 | Cisplatin + Fluorouracil + RT 5day | 02 | N | 310025107 | CHLORAMBUCIL |
| 310005017 | 310006947 | 1.55 | 64 | Curative (C) | 2014-02-26 | 2014-03-03 | Bevacizumab 7.5mg/kg | N | N | 310025107 | BEVACIZUMAB |
| 310005018 | 310010436 | null | 44.6 | Palliative (P) | 2016-06-13 | 2016-06-27 | Cytarabine Low Dose | N | N | 310025119 | CVP R |
| 310005019 | 310010436 | 1.68 | 88.8 | Curative (C) | 2014-02-01 | 2014-02-21 | Cisplatin + Fluorouracil + RT 5day | N | N | 310025119 | VINCRISTINE |
| 310005020 | 310010436 | 1.71 | null | Palliative (P) | 2013-06-12 | 2013-06-16 | CVP R | 02 | N | 310025119 | PAZOPANIB |
| 310005021 | 310010436 | null | 61.8 | null | 2017-04-04 | 2017-04-04 | INTERFERON | null | null | 310025119 | EPIRUBICIN |
| 310005024 | 310002281 | 1.6 | 74.6 | Palliative (P) | 2017-05-05 | 2017-06-03 | CRIZOTINIB | 2 | N | 310025157 | CETUXIMAB + RT |
| 310005025 | 310002281 | null | 53.8 | Neo-adjuvant (N) | 2016-01-04 | 2016-01-07 | ICON8B TRIAL | N | Y | 310025157 | CARBOPLATIN + PEMETREXED |
| 310005026 | 310009245 | 1.7 | 76.7 | Curative (C) | 2016-09-18 | 2016-09-25 | IVE | 02 | N | 310025179 | DOXORUBICIN + OLARATUMAB |
| 310005027 | 310002282 | 1.61 | 68 | Curative (C) | 2017-05-01 | 2017-05-24 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | Y | N | 310025187 | DABRAFENIB + TRAMETINIB |
| 310005028 | 310002283 | 1.75 | 91.4 | Palliative (P) | 2012-11-01 | 2013-04-18 | METHOTREXATE | 2 | N | 310025189 | SCOPE 1 TRIAL |
| 310005029 | 310002284 | 1.77 | 83.8 | Curative (C) | null | 2014-10-12 | Carboplatin + Pemetrexed | N | null | 310025194 | CISPLATIN + PEMETREXED |
| 310005030 | 310002284 | 1.58 | 61.3 | Palliative (P) | 2015-02-17 | 2015-02-18 | CARBOPLATIN + PACLITAXEL + RT | 2 | null | 310025194 | CARBOPLATIN + RT |
| 310005031 | 310002285 | 1.65 | 75 | Adjuvant (A) | 2016-05-06 | 2016-05-20 | Epirubicin | null | null | 310025197 | TRASTUZUMAB EMTANSINE |
| 310005032 | 310002286 | 0 | 69.2 | Palliative (P) | 2017-05-05 | 2017-05-26 | BEP 5 Day | N | N | 310025198 | PAZOPANIB |
| 310005033 | 310002287 | 1.69 | null | Curative (C) | 2016-06-16 | 2016-06-16 | Mini BEAM | 02 | N | 310025199 | LEAM |
| 310005034 | 310002287 | 1.84 | 92 | Neo-adjuvant (N) | 2014-10-15 | 2014-10-29 | LENALIDOMIDE | null | N | 310025199 | CISPLATIN + VINORELBINE |
| 310005035 | 310002288 | null | 71.9 | Curative (C) | null | 2017-05-07 | EVEROLIMUS | N | N | 310025212 | IVA |
| 310005036 | 310002289 | 1.67 | 56 | Curative (C) | 2014-12-21 | 2014-12-22 | Carboplatin + Pemetrexed | N | N | 310025231 | METHOTREXATE INTRATHECAL |